CD4 and neoplasm: In three murine models of melanoma (B16F10), breast (4T1) and colon (CT26) cancer, the majority of the mutated neo-epitopes were recognized by CD4+ T cells, and vaccination with such mutations elicit robust tumor rejection (176).